She graduated from Capital Medical University in 1967 and worked in the Department of Obstetrics and Gynecology at the People’s Hospital of Beijing (Medical University) from 1975 to the present. He studied at Kyoto University Medical School in Japan. He has been engaged in medical, teaching and scientific research in obstetrics and gynecology for many years, specializing in obstetrics and gynecological diseases and gynecological tumors, especially in scientific research, diagnosis, treatment of ovarian cancer and endometrial cancer and treatment of gynecological diseases, establishing more than a thousand files of gynecological malignant tumors and conducting follow-up observations, and exploring the treatment of ovarian epithelial cancer for many years, which has significantly improved its survival rate. In recent years, he has mainly conducted treatment and research on endometrial cancer, carried out and promoted gynecologic laparoscopy, and in recent years promoted cervical cancer screening and standardized treatment of cervical cancer. He was the deputy director of the Chinese Gynecological Oncology Branch, the director of the Department of Obstetrics and Gynecology of the People’s Hospital of Peking University (retired in March 2014), and a member of the 9th, 10th and 11th National People’s Congress. During his tenure, he has participated in writing the clinical series of obstetrics and gynecology, published 400 papers, and won many awards such as the second prize of science and technology of the Ministry of Education of China, the second and third prizes of science and technology achievements of the Chinese Medical Association, the third prize of science and technology of the Chinese Society of Preventive Medicine, and the third prize of science and technology of Beijing). He has trained 63 doctoral students and 4 post-doctoral students, and received the special government allowance issued by the State Council in 1997. Ma Xiaoping, Department of Obstetrics and Gynecology, Jiangsu Provincial Hospital of Integrative Medicine China Obstetrics and Gynecology Network: Good morning, all of you from China Obstetrics and Gynecology Network. At the 1st CSCCP Conference and the 12th National Symposium on Cervical Precancerous Lesions and Cervical Cancer Hotspots, we are honored to have Prof. Wei Lihui from Beijing People’s Hospital, the conference chair of this conference. Hello, Mr. Wei, as the chairman of this conference, can you introduce the academic hotspots of this conference? Prof. Wei Lihui: The 1st CSCCP Conference and the 12th National Symposium on Cervical Precancerous Lesions and Cervical Cancer Hotspots were held in the environment of cervical cancer prevention and control under the guidance of our government. The National Symposium on Cervical Precancerous Lesions and Cervical Cancer Hotspots is a national continuing education program sponsored by the People’s Hospital of Peking University, and this is the twelfth year. After this conference was upgraded to the level of CSCCP, it served to bring the prevention and treatment of cervical cancer from the world to China. Currently, the prevention and treatment of cervical cancer is in full swing around the world, and each country has developed its own cervical cancer prevention and treatment protocols that meet its own characteristics. After decades of development, cervical cancer has become the only disease in the world that can be prevented, controlled and controlled. Therefore, it is hoped that China can also catch up with the international stage of development, and manage and carry out cervical cancer screening and prevention in a more standardized manner. China Obstetrics and Gynecology Network: In this conference, many famous experts from the United States, the United Kingdom and Hong Kong were invited from home and abroad, and they all have their own SCCP organizations. Could Ms. Wei introduce the development process and what are the prospects for the development of the establishment of CSCCP in China? Prof. Wei Lihui: Internationally, to do a good job in cervical cancer prevention and control, there is a need to have a corresponding academic institution to guide the prevention and control work in a more scientific and standardized way. 41 countries have established SCCP organizations. 1964, the US took the lead in establishing ASCCP, and then other countries established their own SCCPs one after another. 1974, the International Federation of Colposcopy and Cervical Pathology ( IFCCP). Over the years, this consortium and the ASCCP in the United States have developed many routine practice guidelines. The establishment of the CSCCP in China is a very significant event. For decades, China has been actively working on cervical cancer prevention and treatment, especially in this decade, the screening of women for both cancers has been carried out and popularized under the organization of the government. In this situation, it is necessary for Chinese scholars to mention the screening of cervical cancer in China to a more orderly and standardized management of routine work through such an organization. The CSCCP platform has a very prominent feature: we have included obstetricians and gynecologists, pathologists, epidemiologists, and some basic research researchers in this platform, hoping to bring together the strengths of various disciplines and academia to do a good job in the prevention and treatment of cervical cancer. China Obstetrics and Gynecology Network: Thank you, Mr. Wei, for your wonderful introduction. You have discussed “Cervical Cancer Screening Prevention and Treatment Strategy” in this conference. Could you please introduce what are the main methods of cervical cancer screening strategy in China at present? With the increase of screening popularity, how is the public acceptance of this? Prof. Li-Hui Wei: The screening methods implemented in China for many years have been closely following foreign standards, and the development abroad has been particularly fast, especially after the discovery of the close relationship between HPV and cervical cancer, cervical cancer screening targeting HPV has been developed rapidly. However, how should China approach these issues rationally? I believe that Chinese physicians should explore the appropriate approach for China in the context of their own national situation. Of course, we should not negate the original summary experience just because a new method is proposed. We have been doing cytological screening and naked eye screening, both of which have undergone long-term, extensive research, while there are now many methods of HPV screening. What we doctors need to do is to make a comprehensive consideration of how to rationally take into account the actual situation and economic situation of each region in China, and not to force a consistent adoption of any method, or to use the best and most expensive method, but to adopt the most effective method, and the effect is the most important This is also my original intention. China Obstetrics and Gynecology Network: At the beginning of your report, you mentioned that there is an extreme shortage of cytologists in China. Perhaps many doctors are not very clear about cytology research, may I ask how to become a qualified cytologist? Prof. Li-Hui Wei: Cytology belongs to a branch of pathology, and there is no standardized system yet. And the pathology department has long focused on pathology and not enough attention to cytology. In the past decade, as more and more cervical cancer is screened, the requirements for cytology have become more and more stringent, and the lack of a system to train cytologists has led to many problems. Overseas cytology is very standardized and requires pathologists to practice for five years before they can become cytologists. In China, there are no formal cytologists and no access system for formal cytologists. Therefore, in the past, some technicians from obstetrics and gynecology often read the films, or some doctors read the films based on their experience, and explore and learn by groping for stones, while lacking a very effective cytology staff. In fact, cytology should not be eliminated at any time, and I think cytology should have its special status and role. Through cytology and immunohistochemistry, doctors can clearly diagnose whether a patient’s condition is a high-grade lesion or a low-grade lesion. Even if the test result is positive, it needs to be further screened by cytology, so cytology in China needs to draw attention and needs to be developed more. Therefore, many pathologists have been invited to this meeting, hoping that they can better support obstetricians and gynecologists in the prevention and control of cervical cancer from the perspective of cytology, from the perspective of cervical pathology, and from the perspective of microscopic examination. China Obstetrics and Gynecology Network: Thank you very much for accepting the interview with China Obstetrics and Gynecology Network. We wish this conference a great success and wish Mr. Wei good health and better development for the obstetrics and gynecology in China.